Abstract: A surgical instrument, has an end effector that includes an ultrasonic blade, and a clamp arm that moves relative to the ultrasonic blade from an opened position toward an intermediate position and a closed position. The clamp arm is offset from the ultrasonic blade to define a predetermined gap in the intermediate position between the opened position and the closed position. A clamp arm actuator connects to the clamp arm and moves from an opened configuration to a closed configuration to direct the clamp arm from the opened position toward the intermediate position and the closed position. A spacer connects with the clamp arm to inhibit movement of the clamp arm from the intermediate position toward the closed position for maintaining the predetermined gap between the clamp arm and the ultrasonic blade.

Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

Abstract: The present invention relates to compositions and methods for detecting motor neuron-specific miRNAs in a population of cells or subject. More particularly, the invention relates to detecting motor neuron-specific miRNAs to detect and treat motor neuron diseases associated with dysregulation of motor neuron-specific miRNAs, such as Amyotrophic Lateral Sclerosis (ALS).

Abstract: The present invention relates to compositions and methods for detecting motor neuron-specific miRNAs in a population of cells or subject. More particularly, the invention relates to detecting motor neuron-specific miRNAs to detect and treat motor neuron diseases associated with dysregulation of motor neuron-specific miRNAs, such as Amyotrophic Lateral Sclerosis (ALS).

Abstract: The disclosed subject matter relates to techniques, laminates and devices used to fabricate thin dielectric or semiconductor membranes including a handling substrate including a photoresist material on a first surface thereof, a semiconductor wafer having a circuit pattern on a first surface and a second surface to be processed and a temporary adhesive layer temporarily bonding the first surface of the semiconductor wafer to the first surface of the handling substrate including the photoresist material.

Abstract: Disclosed are plunger assemblies which include a plunger sleeve, a plunger rod and an axial protrusion disposed within an inner cavity of the plunger sleeve. Application of a distal force onto the plunger via the plunger rod causes the axial protrusion to contact and apply pressure to an engagement surface in the inner cavity. The engagement surface is configured to receive distal force from the end of the axial protrusion. This causes the plunger to elongate and slightly constrict, thus reducing break loose force and facilitating transition from storage mode to dispensing mode of the plunger.

Abstract: The present invention relates to compositions and methods for detecting motor neuron-specific miRNAs in a population of cells or subject. More particularly, the invention relates to detecting motor neuron-specific miRNAs to detect and treat motor neuron diseases associated with dysregulation of motor neuron-specific miRNAs, such as Amyotrophic Lateral Sclerosis (ALS).

Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

Abstract: The present invention relates to compositions and methods for detecting motor neuron-specific miRNAs in a population of cells or subject. More particularly, the invention relates to detecting motor neuron-specific miRNAs to detect and treat motor neuron diseases associated with dysregulation of motor neuron-specific miRNAs, such as Amyotrophic Lateral Sclerosis (ALS).

Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

Abstract: A non-aqueous nail polish consisting of: (a) a film-forming resin selected from the group consisting of vinyl acetate polymers and copolymers, vinyl alcohol polymers and copolymers, vinyl chloride polymers and copolymers, no greater than 5% by weight, based upon the weight of the polish, cellulosic polymers, and combinations thereof; (b) one or more organic solvents; and (c) optionally, an additive selected from the group consisting of plasticizers, adhesion promoters, suspending agents, pigments, effects pigments, colorants, optical brighteners, leveling agents, therapeutic agents, and combinations thereof. When applied to a bare nail surface and dried, the polish forms a film that may be peeled off the nail surface without use of a polish remover.

Abstract: The present invention relates to compositions and methods for detecting motor neuron-specific miRNAs in a population of cells or subject. More particularly, the invention relates to detecting motor neuron-specific miRNAs to detect and treat motor neuron diseases associated with dysregulation of motor neuron-specific miRNAs, such as Amyotrophic Lateral Sclerosis (ALS).

Abstract: Non-aqueous peelable nail polish formulations that, when applied to a bare nail surface, may be peeled off without the use of polish remover.

Abstract: The invention relates to a method for measuring the metabolism of SOD1 in a subject in vivo.

Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

Abstract: The disclosure relates to methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders, and associated processes. Specifically, the disclosure relates to a method for measuring the metabolism of central nervous system derived biomolecules in a subject in vivo. Further disclosed are methods for measuring the in vivo metabolism (e.g. the rate of synthesis, the rate of clearance) of neurally derived biomolecules, such as superoxide dismutase 1 (SOD1).

Abstract: A multi-material, cryogenic, elastomeric closure is provided for sealing a container for samples of cryophilic biological materials, pharmaceuticals or the like. The closure includes at least one cryophilic elastomer having a glass transition temperature (Tg) below the cryogenic temperature to which the sample is to be subjected and at least one non-cryophilic elastomer having a Tg above the cryogenic temperature. The cryophilic and non-cryophilic elastomers are present in such a manner as to maintain a complete seal of the container opening at the cryogenic temperature.

Abstract: A plunger tip for being located on a distal end of a syringe plunger and for sliding sealed engagement with an interior surface of a syringe barrel includes a core constructed of a generally rigid material. The core has a first end for being secured to the plunger, a second end and an endless sidewall between the first and second ends. An elastomeric sleeve at least partially surrounds the endless sidewall of the core.

Abstract: A gas compressor and method according to which a plurality of inlet valve assemblies are angularly spaced around a bore. A piston reciprocates in the bore to draw the fluid from the valve assemblies during movement of the piston unit in one direction and compress the fluid during movement of the piston unit in the other direction and the valve assemblies prevent fluid flow from the bore to the valve assemblies during the movement of the piston in the other direction. A discharge valve is associated with the piston to permit the discharge of the compressed fluid from the bore.